Mobocertinib (Synonyms: AP32788, TAK-788) |
| Catalog No.GC47697 |
Mobocertinib (TAK-788) es un inhibidor de EGFR/HER2 activo e irreversible por vÍa oral. Mobocertinib inhibe potentemente las variantes oncogénicas que contienen mutaciones activadoras de EGFRex20ins con selectividad sobre el EGFR de tipo salvaje. Mobocertinib se puede utilizar en la investigaciÓn de NSCLC.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1847461-43-1
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Mobocertinib is an inhibitor of mutant EGFR and HER2 receptors.1,2 It is selective for the HER2 exon 20 mutants HER2V659E, HER2G660D, HER2G309E, and HER2S310F over wild-type EGFR in Ba/F3 cells.1
1.Chouitar, J., Vincent, S., Brake, R., et al.TAK-788 is a novel and potent tyrosine kinase inhibitor with selective activity against EGFR/HER2AbstractsS811P2(13-32)(2018) 2.Neal, J., Doebele, R., Riely, G., et al.Safety, PK, and preliminary antitumor activity of the oral EGFR/HER2 exon 20 inhibitor TAK-788 in NSCLCAbstractsS599P1(13-44)(2018)
Average Rating: 5 (Based on Reviews and 33 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *